Smokers with Opioid Use Disorder May Have Worse Drug Use Outcomes After Varenicline Than Nicotine Replacement

Overview

Journal J Subst Abuse Treat

Specialty Psychiatry

Date 2019 Aug 3

PMID 31370981

Citations 8

Authors

Rosemarie A Martin

Damaris J Rohsenow

Jennifer W Tidey

Affiliations

Soon will be listed here.

Abstract

Introduction: Smokers with opioid use disorder (OUD) have little success with smoking cessation, possibly due to interactions between nicotine and opioid receptor systems. Smokers with OUD versus non-opioid substance use disorders (NOUD) have not been compared for response to smoking treatment. Data to make this comparison came from our previous study of 12 weeks (plus dose run-up) of varenicline (VAR) versus 12 weeks of nicotine patch (NRT), in a double-placebo design.

Methods: The current study reports secondary analyses comparing smokers with OUD (n = 47) and NOUD (n = 90) on pretreatment smoking, alcohol and drug use, intolerance of physical discomfort, smoking medication adherence, and 3- and 6-month smoking and substance use outcomes (by VAR versus NRT).

Results: Smokers with OUD did not differ on pretreatment alcohol or smoking measures while reporting significantly more drug use days. Smokers with OUD versus NOUD had significantly fewer days adherent to VAR or placebo capsules but not to patches, and were more tolerant of physical discomfort. While smoking and heavy drinking days at follow-ups did not differ by diagnosis, smokers with OUD had significantly more drug use days in months 4-6 when assigned to VAR (16.4 days) than to NRT (8.1 days).

Conclusions: NRT might be a better choice than VAR for smokers with OUD due to lower adherence and more drug use days with VAR. However, this novel comparison of smoking pharmacotherapy response in smokers with OUD versus NOUD needs to be confirmed with larger numbers of participants.

Citing Articles

Nicotine receptor partial agonists for smoking cessation.

Livingstone-Banks J, Fanshawe T, Thomas K, Theodoulou A, Hajizadeh A, Hartman L Cochrane Database Syst Rev. 2023; 5:CD006103.

PMID: 37142273 PMC: 10169257. DOI: 10.1002/14651858.CD006103.pub8.

Nicotine and opioid co-dependence: Findings from bench research to clinical trials.

Custodio L, Malone S, Bardo M, Turner J Neurosci Biobehav Rev. 2021; 134:104507.

PMID: 34968525 PMC: 10986295. DOI: 10.1016/j.neubiorev.2021.12.030.

Timing of smoking cessation treatment integrated into outpatient treatment with medications for opioid use disorder: Feasibility trial.

Felicione N, Ozga J, Dino G, Berry J, Sullivan C, Blank M J Subst Abuse Treat. 2021; 132:108579.

PMID: 34452780 PMC: 8671242. DOI: 10.1016/j.jsat.2021.108579.

Quit ratios for cigarette smoking among individuals with opioid misuse and opioid use disorder in the United States.

Parker M, Weinberger A, Villanti A Drug Alcohol Depend. 2020; 214:108164.

PMID: 32652375 PMC: 7423737. DOI: 10.1016/j.drugalcdep.2020.108164.

Psycho-Social Correlates of Opioid Use Disorder among the US Adult Population: Evidence from the National Survey on Drug Use and Health, 2015-2018.

Haider M, Brown M, Gupta R, Karim S, Olatosi B, Li X Subst Use Misuse. 2020; 55(12):2002-2010.

PMID: 32633664 PMC: 7952032. DOI: 10.1080/10826084.2020.1788086.

References

Krishnan-Sarin S, Rosen M, OMalley S . Naloxone challenge in smokers. Preliminary evidence of an opioid component in nicotine dependence. Arch Gen Psychiatry. 1999; 56(7):663-8. DOI: 10.1001/archpsyc.56.7.663. View

Brown R, Lejuez C, Kahler C, Strong D . Distress tolerance and duration of past smoking cessation attempts. J Abnorm Psychol. 2002; 111(1):180-5. View

Flannery B, Allen J, Pettinati H, Rohsenow D, Cisler R, Litten R . Using acquired knowledge and new technologies in alcoholism treatment trials. Alcohol Clin Exp Res. 2002; 26(3):423-9. View

Hughes J, Keely J, Niaura R, Ossip-Klein D, Richmond R, Swan G . Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res. 2003; 5(1):13-25. View

Prochaska J, Delucchi K, Hall S . A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. J Consult Clin Psychol. 2004; 72(6):1144-56. DOI: 10.1037/0022-006X.72.6.1144. View

Kalman D, Morissette S, George T . Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict. 2005; 14(2):106-23. PMC: 1199553. DOI: 10.1080/10550490590924728. View

Gonzales D, Rennard S, Nides M, Oncken C, Azoulay S, Billing C . Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006; 296(1):47-55. DOI: 10.1001/jama.296.1.47. View

Richter K, Hamilton A, Hall S, Catley D, Cox L, Grobe J . Patterns of smoking and methadone dose in drug treatment patients. Exp Clin Psychopharmacol. 2007; 15(2):144-53. DOI: 10.1037/1064-1297.15.2.144. View

STORY J, Stark M . Treating cigarette smoking in methadone maintenance clients. J Psychoactive Drugs. 1991; 23(2):203-15. DOI: 10.1080/02791072.1991.10472237. View

10.

Britt J, McGehee D . Presynaptic opioid and nicotinic receptor modulation of dopamine overflow in the nucleus accumbens. J Neurosci. 2008; 28(7):1672-81. PMC: 6671549. DOI: 10.1523/JNEUROSCI.4275-07.2008. View

11.

Hajek P . Individual differences in difficulty quitting smoking. Br J Addict. 1991; 86(5):555-8. DOI: 10.1111/j.1360-0443.1991.tb01807.x. View

12.

Liu X, Palmatier M, Caggiula A, Sved A, Donny E, Gharib M . Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats. Psychopharmacology (Berl). 2008; 202(4):589-98. PMC: 2811405. DOI: 10.1007/s00213-008-1335-0. View

13.

Benowitz N . Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2008; 49:57-71. PMC: 2946180. DOI: 10.1146/annurev.pharmtox.48.113006.094742. View

14.

Heatherton T, Kozlowski L, Frecker R, Fagerstrom K . The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991; 86(9):1119-27. DOI: 10.1111/j.1360-0443.1991.tb01879.x. View

15.

Sirota A, Rohsenow D, Mackinnon S, Martin R, Eaton C, Kaplan G . Intolerance for Smoking Abstinence Questionnaire: psychometric properties and relationship to tobacco dependence and abstinence. Addict Behav. 2010; 35(7):686-93. PMC: 3746812. DOI: 10.1016/j.addbeh.2010.02.014. View

16.

Shi Y, Weingarten T, Mantilla C, Hooten W, Warner D . Smoking and pain: pathophysiology and clinical implications. Anesthesiology. 2010; 113(4):977-92. DOI: 10.1097/ALN.0b013e3181ebdaf9. View

17.

Tsui J, Herman D, Kettavong M, Anderson B, Stein M . Chronic pain and hepatitis C virus infection in opioid dependent injection drug users. J Addict Dis. 2011; 30(2):91-7. PMC: 3089758. DOI: 10.1080/10550887.2011.554775. View

18.

Ditre J, Brandon T, Zale E, Meagher M . Pain, nicotine, and smoking: research findings and mechanistic considerations. Psychol Bull. 2011; 137(6):1065-93. PMC: 3202023. DOI: 10.1037/a0025544. View

19.

Fagerstrom K . Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. Nicotine Tob Res. 2011; 14(1):75-8. DOI: 10.1093/ntr/ntr137. View

20.

Tejeda H, Natividad L, Orfila J, Torres O, ODell L . Dysregulation of kappa-opioid receptor systems by chronic nicotine modulate the nicotine withdrawal syndrome in an age-dependent manner. Psychopharmacology (Berl). 2012; 224(2):289-301. PMC: 3482308. DOI: 10.1007/s00213-012-2752-7. View